662 completed, 302 unknown, 289 recruiting, 117 active not recruiting. 625 Not applicable, 81 Phase 4, 79 Phase 2, 70 Phase 3, 25 Phase 1.
Follow Aortic Valve Disease: new trials by email Literature Review of Aortic Valve Disease trials Research Report on Aortic Valve Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aficamten and Patient-Reported Outcomes in Real-World nHCM receiving aficamten - Hypertrophic Cardiomyopathy (HCM) | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2027-06-01 | 2026-09-29 | |
| High Flow Nasal Oxygenation in Transcatheter Aortic Valve Replacement Procedures. TAVR-Highflow II Oxygen therapy during sedation provided via high nasal cannulae (60L/min at 60% FiO2), Oxygen therapy during sedation delivered via nasal cannulae at 5L/min - Aortic Stenosis Treated With TAVI, Sedation; Aged; Hemodynamics | Not applicable | Not yet recruiting | Hospital Clinic of Barcelona | 452 | 2027-01-01 | 2026-09-18 |
| A Prospective, Multi-centre, Single Arm, Pivotal Clinical Study to Determine the Safety and Effectiveness of Crea Aortic Valve for Use as a Replacement Aortic Heart Valve Investigational Transcatheter Aortic Valve Replacement System - Aortic Valve Stenosis, Severe Aortic Stenosis | Not applicable | Not yet recruiting | Onecrea Medical Inc. | 30 | 2026-12-04 | 2026-07-29 |
| Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy Beta-Blocker Sequential Tapering and Discontinuation, Beta-Blocker Baseline Stable-Dose Maintenance - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Not applicable | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 286 | 2026-12-01 | 2026-09-11 |
| Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis Dapagliflozin (DAPA), Spironolactone (drug), Spironolactone + Dapagliflozin - Aortic Stenosis | Phase 2 | Not yet recruiting | University College, London | 445 | 2026-12-01 | 2026-09-11 |
| Safety and Clinical Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve in Patients With Severe Aortic Stenosis INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart Valve - Aortic Stenosis Senile, Aortic Stenosis Symptomatic | Not applicable | Not yet recruiting | Braile Biomedica Ind. Com. e Repr. Ltda. | 40 | 2026-11-01 | 2026-09-08 |
| SYMmetric Valve fraME Expansion To Reduce hYpoattenuated Leaflet Thickening After Balloon-expandable TAVI: the SYMMETRY Trial Double-TAP post-dilatation - Aortic Valve Stenosis and/or Insufficiency, Hypoattenuated Leaflet Thickening | Not applicable | Not yet recruiting | Erasmus Medical Center | 422 | 2026-11-01 | 2026-10-16 |
| Prospective Multicenter Study Evaluating Myval TAVR Safety and Effectiveness in High-risk Severe AR Myval THV series - Aortic Regurgitation, Aortic Disease | Not applicable | Not yet recruiting | Ceric Sàrl | 164 | 2026-10-30 | 2026-08-07 |
| NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices SESAME Procedure - Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction | Not applicable | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 200 | 2026-10-27 | 2026-10-22 |
| Human Experimental Models of Pain (HEMP) Placebo, Naproxen, Pregabalin - Acute Pain | Not applicable | Not yet recruiting | National Center for Complementary and Integrative Health (NCCIH) | 25 | 2026-10-27 | 2026-10-22 |
| Balloon- Versus Self-Expanding Intraannular TAVI in Small Aortic Annuli Meril Octapro+ THV System, Abbott Navitor/Navitor Vision THV system - Aortic Valve Stenosis | Not applicable | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 510 | 2026-10-26 | 2026-08-31 |
| Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy QG101-23-0 enteric coated capsule (60/120/240/360 mg BID), QG101-23-0 enteric coated capsule (120/240/360/480mg BID) - Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM) | Phase 2 | Not yet recruiting | Amckaus PTY LTD. | 56 | 2026-10-01 | 2026-06-30 |
| Echocardiographic Perspectives on Transient Mitral Regurgitation After Septal Myectomy Hypertrophic Cardiomyopathy | Not yet recruiting | University Health Network, Toronto | 150 | 2026-10-01 | 2026-10-14 | |
| Coronary Sinus Reducer Objective Impact on SymptoMs, Ischaemia and miCrovascular Resistance in Non-obstructive Hypertrophic CardioMyopathy Coronary sinus reducer, Placebo procedure - Hypertrophic Cardiomyopathy | Not applicable | Not yet recruiting | Imperial College London | 50 | 2026-10-01 | 2026-10-08 |
| The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial Beta-lactam antibiotic with spectrum for Enterococcus faecalis, Cephalosporin - Aortic Valve Stenosis | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 1986 | 2026-10-01 | 2026-10-05 |
| Comparing Suture vs. Combined Closure Strategies for Large Blood Vessel Access in Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI) Single Suture-Based Vascular Closure Device, Extravascular Collagen Plug-Based Closure Device - Aortic Valve Stenosis, Postoperative Complications | Not applicable | Not yet recruiting | University Hospital, Basel, Switzerland | 705 | 2026-10-01 | 2026-08-04 |
| Molecular Imaging to Identify Predictors of Aortic Valve Disease Activity AORTIC VALVE DISEASES, Calcification; Heart | Not yet recruiting | Massachusetts General Hospital | 100 | 2026-09-30 | 2026-09-16 | |
| Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy Mavacamten - Obstructive Hypertrophic Cardiomyopathy (oHCM) | Not yet recruiting | Bristol-Myers Squibb | 800 | 2026-09-30 | 2026-09-29 | |
| Coronary Access After Evolut FX Plus TAVI: Impact of Commissural Alignment and the Large-Cell Frame Design: ACCESS-FX+ Registry Severe Aortic Stenosis | Not yet recruiting | Yonsei University | 122 | 2026-09-29 | 2026-09-10 | |
| Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression Vericiguat (BAY1021189), Placebo - Calcific Aortic Valve Disease, AORTIC VALVE DISEASES | Phase 2 | Recruiting | West China Hospital | 238 | 2026-09-24 | 2026-09-25 |
Showing 20 of 1630. Sign in to see all of them.
Aortic Valve Stenosis (986) · Cardiomyopathy, Hypertrophic (352) · Aortic Valve Insufficiency (165) · Heart Valve Diseases (109) · Coronary Artery Disease (77) · Cardiovascular Diseases (65) · Bicuspid Aortic Valve Disease (62) · Heart Failure (62) · Mitral Valve Insufficiency (56) · Heart Diseases (48) · Cardiomyopathy, Dilated (38) · Aortic Valve, Calcification of (36) · Cardiomyopathies (32) · Hypertrophy, Left Ventricular (30)
Heart Diseases (1582) · Cardiovascular Diseases (1565) · Heart Valve Diseases (1521) · Ventricular Outflow Obstruction (1001) · Aortic Valve Stenosis (384) · Aortic Stenosis, Subvalvular (353) · Cardiomyopathies (326) · Pathological Conditions, Signs and Symptoms (253) · Vascular Diseases (220) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (194) · Pathologic Processes (166) · Congenital Abnormalities (132) · Genetic Diseases, Inborn (111) · Cardiovascular Abnormalities (110)
Transcatheter Aortic Valve Replacement (154) · MYK-461 (37) · Echocardiography (22) · Aspirin (14) · Exercise (13) · Clopidogrel (12) · Blood Specimen Collection (8) · Standard of Care (8) · Hematologic Tests (7) · Magnetic Resonance Imaging (7) · Magnetic Resonance Spectroscopy (7) · Saline Solution (7) · Anesthesia, Local (6) · Electrocardiography, Ambulatory (6) · Losartan (6)
Edwards Lifesciences (45) · National Heart, Lung, and Blood Institute (NHLBI) (38) · Abbott Medical Devices (31) · Bristol-Myers Squibb (25) · Medtronic Cardiovascular (18) · Xijing Hospital (18) · University Hospital, Montpellier (17) · Boston Scientific Corporation (16) · China National Center for Cardiovascular Diseases (16) · Institut für Pharmakologie und Präventive Medizin (16) · Assistance Publique - Hôpitaux de Paris (15) · Second Affiliated Hospital, Zhejiang University, School of Medicine (15) · Chinese Academy of Medical Sciences, Fuwai Hospital (14) · Oslo University Hospital (14) · The Cleveland Clinic (14)
United States (378) · Germany (231) · France (186) · United Kingdom (168) · Italy (162) · China (159) · Netherlands (133) · Canada (123) · Spain (104) · Denmark (87) · Switzerland (73) · Belgium (62) · Austria (51) · Poland (46) · Sweden (46)
Hendrik Treede, MD (7) · Martin B Leon, MD (6) · John Webb, MD (5) · Michael Reardon, MD (5) · Robert J Lederman, M.D. (5) · Barathi Sethuraman (4) · Manfred Boehm, M.D. (4) · Raj Makkar, MD (4) · Seung-jung Park, MD (4) · Vinod Thourani, MD (4) · Alibek Kh Mustafin, Professor (3)
PMID 20961243, PMID 33962483, PMID 21639811, PMID 29555836, PMID 31690104, PMID 31883339, PMID 35041482, PMID 38710669, PMID 42636950, PMID 12831818, PMID 24678937, PMID 27040324, PMID 31525069, PMID 32774184, PMID 34581194, PMID 35321859, PMID 35595203, PMID 35656983, PMID 36515976, PMID 16980116, PMID 20096533, PMID 20188503, PMID 20566953, PMID 21273254, PMID 22424519, PMID 22443479, PMID 23349346, PMID 24621999, PMID 24657695, PMID 25533774, PMID 25655063, PMID 25788234, PMID 26139739, PMID 26384204, PMID 26436963, PMID 26491110, PMID 26896466, PMID 27601429, PMID 27609682, PMID 27815101, PMID 28279376, PMID 28306757, PMID 28321003, PMID 28527771, PMID 28912187, PMID 29171730, PMID 29912142, PMID 29914867, PMID 30031719, PMID 30250733
2023 (9), 2019 (6), 2015 (2), 2025 (2), R01AG089981 (2), R21HL150373 (2), 1RC1LM010526 (1), 2009 (1), 2016 (1), 2017 (1), 2018 (1), 268201000048C-5-0-1 (1), K23HL004444 (1), K23HL078901 (1), K23HL136902 (1)